New COPD drug Hemay005 enters Mid-Stage trial
NCT ID NCT07314242
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2a trial tests whether Hemay005 can reduce lung inflammation in people with moderate to severe COPD. About 120 adults will take Hemay005, the existing drug roflumilast, or a placebo for 12 weeks. Researchers will measure changes in sputum and blood markers to see if Hemay005 is safe and effective.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Hemay005
What this could lead to
If it works, this could point toward a new treatment option for COPD that reduces lung inflammation and improves breathing.
What could go wrong
This is an early Phase 2a study with only 120 participants, so results may not apply to everyone. The drug may not work better than existing treatments or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China People's Armed Police Force Characteristic Medical Center
Tianjin, 300162, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Fourth Central Hospital
Tianjin, 300074, China
Contact